Human multidrug resistance protein 1 (MRP1) has a total of 17 transmembrane (TM) helices arranged in three membrane-spanning domains, MSD0, MSD1, and MSD2, with a 5 ؉ 6 ؉ 6 TM configuration. 
Human multidrug resistance protein 1 (MRP1) is a member of the "C" branch of the ATP-binding cassette transporter (ABC) superfamily and has been designated ABCC1. The predicted topology of MRP1 consists of a typical P-glycoprotein-like core region, composed of two membrane-spanning domains (MSDs 1and 2), each with six transmembrane (TM) ␣-helices, and two nucleotide binding domains. In addition, MRP1 contains an NH 2 -terminal MSD, MSD0, which consists of five TMs with an extracellular NH 2 terminus (Bakos et al., 1996; Hipfner et al., 1997; Kast and Gros, 1997) . Thus, the protein contains three MSDs with a total of 17 predicted TM helices (5 ϩ 6 ϩ 6; Fig. 1 ).
MRP1 confers resistance to many commonly used natural product chemotherapeutic agents including anthracyclines, Vinca alkaloids, and epipodophyllotoxins, as well as methotrexate and certain heavy metal oxyanions (Cole et al., 1992 (Cole et al., , 1994 . However, transport of unmodified drugs by MRP1 is both GSH-and ATP-dependent (Rappa et al., 1997; Loe et al., 1998; Renes et al., 1999) . In some cases, GSH appears to be cotransported with these compounds (Rappa et al., 1997; Loe et al., 1998; Renes et al., 1999) . Detailed in vitro transport measurements using MRP1-enriched inside-out membrane vesicles have demonstrated that MRP1 is capable of directly transporting many glutathione-, glucuronide-, and sulfate-conjugated organic anion conjugates, such as the glutathione conjugate cysteinyl leukotriene 4 (LTC 4 ), and glucuronate conjugate 17␤-estradiol 17-(␤-D-glucuronide) (E 2 17␤G) in an ATP-dependent manner (Muller et al., 1994; Jedlitschky et al., 1996; Loe et al., 1996a,b) . The mechanism by which MRP1 binds and transports such structurally unrelated cytotoxic drugs and conjugated organic anions remains an active area of study. In the absence of a crystal structure of the protein, identification of amino acid residues involved in determining substrate specificity and transport activity, coupled with structural predictions, has provided valuable insights into the mechanism by which MRP1 recognizes structurally diverse compounds.
Photoaffinity labeling studies have implicated TMs 10, 11, 16, and 17 of MRP1 as components of the substrate binding pocket(s) of the protein (Daoud et al., 2001; Qian et al., 2001 Qian et al., , 2002 Mao et al., 2002) . Previously, we have demonstrated that certain amino acid residues with hydrogen-bonding side chains located in the putative TM11 and -17 of MRP1 are important, either for overall activity or substrate specificity of the protein (Ito et al., 2001; Zhang et al., 2001a Zhang et al., ,b, 2002 Zhang et al., , 2004 Haimeur et al., 2002 Haimeur et al., , 2004 Koike et al., 2002) . Trp 553 and Pro 557 , located within TM10 of MRP1, have also been shown to be important for the transport activity of the protein (Koike et al., 2002 . More recently, charged residues Arg 1197 , Arg 1202 , and Glu 1204 , and the polar residue Trp 1198 , predicted to be within TM16, have been reported to be essential for function Situ et al., 2004) . We have now examined the role of additional residues with hydrogen-bonding capability within TM10 and -16. In TM10, Thr 550 , Thr 552 , Thr 556 , Thr 564 , and Thr 570 were individually mutated to Ala, and Tyr 568 was mutated to Ala, Ser, Phe, and Trp. Asn 1208 within TM16 was replaced by Ala. These mutant proteins were then stably expressed in human embryonic kidney (HEK293) cells, and the transfectants were characterized with respect to their drug resistance profiles, as well as their ability to transport LTC 4 , E 2 17␤G, and GSH. Mutation N1208A in TM16 had no detectable effect on the function of MRP1. However, two polar residues, Thr 550 and Thr 556 , located in TM10, play an important role in determining the drug resistance profile, and the aromatic side chain of the residue at position 568 of TM10 of MRP1 is important for E 2 17␤G transport. Site-Directed Mutagenesis. Mutation T564A was generated using the Transformer Site-Directed Mutagenesis kit (BD Biosciences Clontech, Palo Alto, CA). Templates were prepared as described previously . Mutagenesis was then performed according to the manufacturer's instructions using a selection primer, 5Ј-GAGAGTGCACGATATCCGGT-GTG-3Ј, that mutates a unique NdeI site in the vector to an EcoRV restriction site. An oligonucleotide bearing the mismatched base at the residue to be mutated (underlined) was synthesized by ACGT Corp. (Toronto, ON, Canada) with the following sequence: 5Ј-GGTGGCCTTGTGCGCATTTGCCGTC-TAC-3Ј. Mutations T550A, T552A, T556A, Y568A, Y568S, Y568F, Y568W, T570A, and N1208A were generated using the Quikchange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA). Mutagenesis was then performed according to the manufacturer's instructions. Oligonucleotides bearing mismatched bases at the residues to be mutated (underlined) were synthesized by ACGT Corp. with the following sequences: T550A, 5Ј-GTCAGCCGTGGG-CGCCTTCACCTGGGT-3Ј; T552A, 5Ј-CGTGGGCACCTTCGCCTGGGTC-TGCAC-3Ј; T556A, 5Ј-CACCTGGGTCTGCGCGCCCTTTCTGGT-3Ј;  Y568A, 5Ј-TGCACATTTGCCGTCGCCGTGACCATTGACGA-3Ј; Y568S,  5Ј-TGCACATTTGCCGTCTCCGTGACCATTGACGA-3Ј; Y568F, 5Ј-TGC-ACATTTGCCGTCTTCGTGACCATTGACGA-3Ј; Y568W, 5Ј-TGCACAT-TTGCCGTCTGGGTGACCATTGACGA-3Ј; T570A, (5Ј-TGCCGTCTACG-TGGCCATTGACGAGAACAAC-3Ј; and N1208A, 5Ј-GCCGTGCGGCTG-GAGTGTGTGGGCGCC-3Ј. After confirming all mutations by DNA sequencing (ACGT Corp.), DNA fragments containing the desired mutations were transferred into pCEBV7-MRP1. After reconstructing full-length expression vectors containing the mutations, the integrity of the mutated inserts and cloning sites was verified by DNA sequencing (ACGT Corp.).
Materials and Methods

Materials
Cell Lines and Tissue Culture. Stable transfection of HEK293 cells with the pCEBV7 vector containing the wild-type and mutant MRP1 cDNAs has been described previously (Zhang et al., 2001a) . Briefly, HEK293 cells were transfected with pCEBV7 vectors containing mutant MRP1 using Fugene6 (Roche Molecular Biochemicals, Basel, Switzerland) according to the manufacturer's instructions. After ϳ48 h, the transfected cells were supplemented with fresh medium containing 100 g/ml hygromycin B. Approximately 3 weeks after transfection, the hygromycin B-resistant cells were cloned by limiting dilution and the resulting cell lines were tested for high level expression of the mutant proteins.
Determination of Protein Levels in Transfected Cells. Plasma membrane vesicles were prepared by centrifugation through sucrose, as described previously (Loe et al., 1996b ; Zhang et al., 2001a) . After determination of protein levels by the Bradford assay (Bio-Rad, Hercules, CA), total membrane protein (0.5 g, 1.0 g, and 1.25 g) from transfectants expressing wild-type MRP1 and various mutant proteins were resolved on a 7.5% SDS-polyacrylamide gel electrophoresis and then transferred onto Immobilon-P polyvinylidene difluoride membranes (Millipore, Bedford, MA). The proteins were detected with the mAb, MRPm6 (Alexis Biochemicals, San Diego, CA), and the signal was enhanced using Renaissance chemiluminescence reagent (PerkinElmer Life Sciences). Relative levels of MRP1 expression were determined by densitometry of exposed films. Confocal Microscopy. Confocal microscopy was carried out as described previously (Zhang et al., 2001a,b) . Briefly, ϳ5 ϫ 10 5 stably transfected HEK293 cells were seeded in each well of a six-well tissue culture dish on coverslips. When the cells had grown to confluence, they were washed once in PBS and then fixed with 2% paraformaldehyde in PBS, followed by permeabilization using digitonin (0.25 mg/ml in PBS). MRP1 proteins were detected with the monoclonal antibody MRPm6. Antibody binding was detected with Alexa Fluor 488 (Molecular Probes, Eugene, OR) anti-mouse IgG (HϩL) (FabЈ) 2 fragment. Nuclei were stained with propidium iodide. Localization of MRP1 in the transfected cells was determined using a Meridian Insight confocal microscope (Meridian Instrument Company, Inc., Kent, WA) (filter, 620/40 nm for propidium iodide; 530/30 nm for Fluor 488).
LTC 4 , E 2 17␤G, and GSH Transport by Membrane Vesicles. Plasma membrane vesicles were prepared as described previously, and ATP-dependent transport of [ 3 H]LTC 4 into the inside-out membrane vesicles was measured by a rapid filtration technique (Loe et al., 1996b ; Zhang et al., 2001a) . Briefly, vesicles (10 g of protein) were incubated at 23°C in 100 l of transport buffer (50 mM Tris-HCl, 250 mM sucrose, 0.02% sodium azide, pH7.4) containing ATP or AMP (4 mM), 10 mM MgCl 2 , and [ 3 H]LTC 4 (50 nM, 200 nCi). At the indicated times, 20-l aliquots were removed and added to 1 ml of ice-cold transport buffer, followed by filtration under vacuum through glass fiber filters (type A/E; Gelman Sciences, Dorval, QC, Canada). Filters were immediately washed twice with 4 ml of cold transport buffer. The bound radioactivity was determined by scintillation counting. All data were corrected for the amount of [ 3 H]LTC 4 that remained bound to the filter in the absence of vesicle protein (usually Ͻ5% of the total radioactivity). [
3 H]LTC 4 uptake was expressed relative to the total protein concentration in each reaction. ATP-dependent uptake of [ 3 H]E 2 17␤G (400 nM, 120 nCi) was measured as described for [ 3 H]LTC 4 , except that the temperature used was 37°C.
K m and V max values of ATP-dependent [ 3 H]LTC 4 uptake by membrane vesicles (2.5 g of protein) were measured at various LTC 4 concentrations (0.01-1 M) for 1 min at 23°C in 25 l of transport buffer containing 4 mM ATP and 10 mM MgCl 2 , followed by linear transformation using a HanesWoolf plot. Kinetic parameters of ATP-dependent [ 3 H]E 2 17␤G (0.1-16 M) uptake were determined as described for [ 3 H]LTC 4 , except that the temperature used was 37°C.
GSH uptake was also measured by rapid filtration with membrane vesicles (20 g of protein) incubated at 37°C for 20 min in a 60-l reaction volume with [ 3 H]GSH (100 M, 300 nCi) in the absence and presence of verapamil (100 M). To minimize GSH catabolism by ␥-glutamyltranspeptidase during transport, membranes were preincubated in 0.5 mM acivicin for 10 min at 37°C before measuring [
3 H]GSH uptake in the presence of verapamil (100 M).
Chemosensitivity Testing. Drug resistance was determined using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described previously (Cole et al., 1994; Zhang et al., 2001a) . Mean values of quadruplicate determinations (ϮS.D.) were plotted using GraphPad software (GraphPad Software Inc., San Diego, CA). IC 50 values were obtained from the best fit of the data to a sigmoidal curve. Relative resistance is expressed as the ratio of the IC 50 value of cells transfected with MRP1 expression vectors compared with cells transfected with empty vector. Resistance was determined in three or more independent experiments. (Fig. 1) . The episomal expression vector, pCEBV7, containing mutated forms of MRP1 cDNAs, was used to stably transfect HEK293 cells, and populations of transfected cells were selected in hygromycin B. The resultant stably transfected cell populations were cloned by limiting dilution, and subpopulations expressing high levels of MRP1 mutant proteins were used in subsequent studies. The levels of mutant proteins relative to wild-type MRP1 in previously characterized HEK transfectants were determined by immunoblotting and densitometry ( Fig. 2A) . The expression levels of these mutant proteins in stably transfected HEK293 cells ranged from 50 to 90% of wild-type MRP1. Endogenous MRP1 in HEK293 cells transfected with the empty vector was undetectable under the conditions used (data not shown).
Results
Expression of Mutant MRP1 in
To determine whether these mutations influenced trafficking of the protein, we compared the subcellular localization of wild-type and mutant MRP1 by confocal microscopy. The subcellular distribution of the mutated proteins assessed by immunoreactivity with the MRP1-FIG. 2. Expression of mutant MRP1 in stably transfected HEK293 cells. A, expression levels of wild-type and mutant MRP1 proteins in membrane vesicles isolated from stably transfected HEK293 cells were determined by immunoblotting of membrane vesicle preparations and densitometry as described. Blots were probed with the MRP1-specific mAb MRPm6. The numbers below the blot refer to the levels of the mutant MRP1 proteins relative to the levels of wild-type MRP1 proteins in membrane vesicles prepared from the stably transfected HEK293 cells. Values are the mean of three independent experiments. B, the subcellular localization of wild-type and mutant MRP1 was determined by confocal microscopy as described. MRP1 was detected using mAb MRPm6. Location of MRP1 is indicated in green. Nuclei were stained with propidium iodide and are shown in red. Transfectants tested were expressing wild-type or mutant MRP1 as indicated in the figure. An x-y optical section of the cells is shown to illustrate the distribution of the wild-type and mutant proteins between plasma and intracellular membranes.
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at ASPET Journals on April 18, 2017 dmd.aspetjournals.org specific mAb MRPm6 was indistinguishable from that of cells expressing wild-type protein (Fig. 2B) . In all cases, strong plasma membrane staining was observed, indicating that trafficking was unaffected. To determine whether any of the mutations altered the efficiency with which the protein transported LTC 4 and E 2 17␤G, we examined ATP-dependent uptake of these compounds by membrane vesicles prepared from HEK transfectants expressing each of the mutant proteins (Fig. 3) . The levels of LTC 4 uptake by vesicles prepared from HEK transfectants expressing either wild-type or mutant MRP1 were proportional to the relative expression levels of the wild-type and mutant proteins (Fig. 3, A to C) . Thus, these polar residues may not be involved in the binding and transport of LTC 4 . ATP-dependent transport of [ 3 H]E 2 17␤G was also examined (Fig. 3,  D to F (Fig. 4A) . The effects of these mutations on the ability of MRP1 to transport LTC 4 and E 2 17␤G were then examined (Fig. 4 , B and C). Like mutation Y568A, substitution of Tyr 568 with Ser did not affect the transport of LTC 4 but decreased E 2 17␤G transport. However, replacement of Tyr 568 with the more conservative residues, Phe and Trp, had no effect on transport of either compound (Fig. 4, B and C) . Thus, the aromaticity or steric bulk of the residue at position 568, but not the side chain polarity, plays a role in determining the efficiency of transporting the conjugated estrogen. . To more precisely determine the influence of mutation Y568A on the ability of MRP1 to transport E 2 17␤G, we compared kinetic parameters for the wild-type and mutant proteins (Fig. 5) . For wild-type MRP1 and Y568A, the K m and normalized V max values for LTC 4 uptake were essentially identical. Linear regression using a Hanes-Woolf transformation yielded values of 115 nM and 143 nM, and 76.8 pmol/mg/min and 64 pmol/mg/min, for the K m and V max values of wild-type and Y568A proteins, respectively (Fig. 5, B and C) . For E 2 17␤G transport, a comparable analysis yielded K m values of 1.4 M and 5.4 M and normalized V max values of 170 pmol/mg/min and 190 pmol/mg/min for wild-type and mutant proteins, respectively (Fig. 5, D teins were determined using MTT assays. The results are presented as relative drug resistance factors in Table 1 . Mutation of Asn 1208 in TM16 had no effect on the ability of MRP1 to confer resistance to any of the three classes of drugs tested. However, mutation of two Thr residues in TM10 altered the drug resistance profile (Table 1) . Substitution T550A reduced resistance to doxorubicin approximately 2-fold and increased resistance to vincristine approximately 4.5-fold, but had no effect on VP-16 resistance. In contrast, mutation T556A reduced the resistance to both VP-16 and doxorubicin approximately 2-fold without affecting vincristine resistance. Thus, elimination of the polarity of the side chains of residues at positions 550 and 556 differentially affects the drug resistance profile of MRP1, suggesting that these two Thr residues may interact directly with drug substrates.
Transport of [ 3 H]GSH by Wild-Type and Mutant MRP1.
We have shown that mutations T550A and T556A both affect the ability of MRP1 to confer drug resistance, whereas mutation Y568A only influenced the transport of E 2 17␤G. One major distinction between MRP1-mediated transport of substrates such as LTC 4 and E 2 17␤G, and drugs such as vincristine and daunorubicin, is a requirement for GSH, which may be cotransported with the unmodified drug (Rappa et al., 1997; Renes et al., 1999; Loe et al., 1998) . Previously, we have reported that MRP1 exhibits low levels of ATP-dependent GSH transport that can be dramatically stimulated by verapamil (Loe et al., 2000) . Thus, we examined the effects of mutations made in TM10 and -16 on verapamil-stimulated GSH transport by MRP1 to determine whether any mutations that affected drug resistance also influenced the GSH transport (Fig. 6 ). As observed with the effects of the mutations on LTC 4 transport, none of these mutations had any significant effect on verapamil-stimulated GSH transport, consistent with the suggestion that they modify interactions between MRP1 and the drug, rather than altering the ability to bind and transport GSH.
Discussion
Photolabeling studies indicate that amino acids in predicted TM helices 10, 11, 16, and 17 are probable components of the substrate binding pocket of MRP1 (Daoud et al., 2001; Qian et al., 2001; Mao et al., 2002) . Mutational studies have also shown that a number of polar amino acids in TM helices 11, 16, and 17 are major determinants of substrate specificity and overall transport activity of the protein (Ito et al., 2001; Zhang et al., 2001a Zhang et al., ,b, 2002 Zhang et al., , 2004 Haimeur et al., 2002 Haimeur et al., , 2004 Koike et al., 2002) . The majority of the functionally important polar residues in TM11 and TM17 are in the predicted inner leaflet region of the membrane (Ito et al., 2001; Zhang et al., 2001b Zhang et al., , 2002 Zhang et al., , 2004 Haimeur et al., 2004; Situ et al., 2004) . Mapping of these residues onto an energy-minimized model of the tertiary structure of MSD1 and MSD2 of MRP1 suggests that most of their side chains project toward, or line, a central cavity presumed to be the translocation pathway of the protein (Campbell et al., 2004) . Thus, they are available to interact with substrate or the side chains of amino acids in neighboring TM helices (Fig. 7) . To provide additional experimental evidence for or against the proposed structure, we have extended the mutational analysis to polar residues in TM10 and mutated the remaining uncharacterized polar residue in TM16.
The predicted outer leaflet region of TM16 is devoid of polar amino acids (Fig. 1B) , and mutation of the vicinal cysteine residues, Cys 1205 and Cys 1209 , was found previously to have no effect on substrate specificity or overall activity (Olsen et al., 1998) . Similarly, mutation of Arg 1202 had no effect on transport activity of MRP1. Conversely, replacement of Glu 1204 with Leu or Arg 1197 with Glu or Lys affected either substrate specificity or overall transport activity of MRP1 (Situ et al., 2004) . Mutation of Trp 1198 to Ala also dramatically decreased overall transport activity (Koike et al., 2002) . Based on the model shown (Fig. 7) , these amino acids, and several other functionally important residues in TM17, cluster in the predicted inner leaflet region of the two TMs with their side chains projecting toward TMs 10 and 11. The remaining polar residue in TM16, Asn 1208 , is also predicted to project into the translocation pore (Fig. 7) . However, mutation of Asn 1208 had no effect on transport or drug resistance. Similarly, mutation of two polar residues in TM17, Ser 1235 and Gln 1237 , with side chains predicted to project into the pore, also had no effect (Fig. 7) . In all cases, these residues are located toward the outer leaflet of the membrane relative to the cluster of amino acids that affect substrate specificity or overall activity.
Mutation of Trp 553 and Pro 557 in TM10 alters the overall transport activity of MRP1 rather than substrate specificity (Koike et al., 2002 . To further examine the role of amino acids in TM10, we mutated five Thr residues and Tyr 568 . Mutations of Thr 552 , Thr 564 , and Thr 570 had no effect on either the drug resistance profile or organic anion transport activity. Thr 552 is predicted to be in the inner leaflet region of the membrane, but its side chain projects away from the predicted pore. As found with polar residues in TMs 11, 12, 16, and 17 of MRP1 that do not affect substrate specificity, Thr 564 and Thr 570 are predicted to be located in the outer leaflet region of TM10. Similarly, conservative mutation of Tyr 568 , which is also predicted to 
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FIG. 5. Kinetics of ATP-dependent [
3 H]LTC 4 and [ 3 H]E 2 17␤G uptake. A, expression levels of wild-type and mutant MRP1 proteins in membrane vesicles isolated from transiently transfected HEK293 cells were determined by immunoblotting of membrane vesicle preparations and densitometry as described in the legend to Fig. 2A . The numbers below the blot refer to the levels of mutant MRP1 proteins relative to the levels of wild-type MRP1 protein in membrane vesicles prepared from the stably transfected HEK293 cells. B and C, the initial rate of ATP-dependent [ 3 H]LTC 4 uptake by membrane vesicles prepared from HEK293 cells transfected with wild-type or mutant proteins was measured at various LTC 4 concentrations (0.01-1 M) for 1 min at 23°C as described. D and E, [ 3 H]E 2 17␤G uptake was determined as described for [
3 H]LTC 4 except that the reactions were carried out at 37°C with various concentrations of E 2 17␤G (0.1-16 M). Values are the mean Ϯ S.D. of triplicate determinations in a single experiment. Similar results were obtained from one more experiment. B and D, data were plotted as V 0 versus [S] to confirm that the concentration range selected was appropriate to observe both zero-order and first-order rate kinetics. C and E, data were plotted as [S]/V versus [S] . The transfectants tested were HEK MRP1 (f), and HEK MRP1Y568A (OE). Kinetics parameters for LTC 4 and E 2 17␤G transport were determined from nonlinear and linear regression analysis of the combined data. Details of K m and V max values for wild-type and mutant MRP1 are provided under Results.
TABLE 1
Relative drug resistance of HEK293 cells transfected with wild-type and mutant MRP1
The resistance of HEK293 cells transfected with expression vectors encoding wild-type and mutant MRP1 relative to that of cells transfected with empty vector was determined using a tetrazolium salt-based microtiter plate assay. The relative resistance factor was obtained by dividing the IC 50 values for wild-type/mutant MRP1-transfected cells by the IC 50 value for control transfectants. The values shown represent the mean (ϮS.D.) of relative resistance values determined from three independent experiments. Resistance factors normalized for differences in the levels of mutant proteins expressed in the transfectant populations used are shown in parentheses.
Transfectant
Drug (Relative Resistance Factor) Vincristine VP-16 Doxorubicin be in the outer leaflet, to either Phe or Trp had no effect on substrate specificity. However, nonconservative mutation to Ala or Ser selectively decreased transport of E 2 17␤G without affecting the transport of LTC 4 or GSH, or resistance to any drug tested. Mutation of two of the five Thr residues, Thr 550 and Thr 556 , differentially affected drug resistance without altering transport of the organic anion conjugates tested. Thr 550 and Thr 556 are predicted to be in the inner leaflet region of TM10, and the side chains of both residues align with that of Trp 553 . Taken together, these findings confirm the role of TM10 in determining substrate specificity and overall transport activity of MRP1.
We have previously proposed that hydrogen bonding may be a common form of interaction between MRP1 and its substrates (Ito et al., 2001; Zhang et al., 2001a Zhang et al., ,b, 2002 Zhang et al., , 2003a . The differential effect of eliminating the hydrogen-bonding potential of Thr 550 and Thr 556 on drug resistance supports this suggestion. However, since the transport of vincristine and doxorubicin by MRP1 is GSH-dependent, we also examined the possibility that these mutations might influence interaction of MRP1 with GSH rather than drug Renes et al., 1999) . Nonetheless, the Thr 550 and Thr 556 mutations had no effect on basal or verapamil-stimulated GSH transport (Loe et al., 2000) . Overall, the effects of these two mutations suggest that Thr 550 and Thr 556 may form hydrogen bonds with some drug substrates, such as doxorubicin and VP-16. The increase in resistance to vincristine observed with the T550A mutation may be attributable to the smaller size of the Ala side chain that favors transport of the larger drug. Similar behavior was observed after Ala mutations of Asn 597 and Asn 1245 in TM11 and TM17, respectively . Like the T550A mutation, these mutations decreased resistance to VP-16 and increased resistance to vincristine. Thr 550 , Thr 556 , and the previously identified Trp 553 in TM10, together with Phe 594 in TM11, are predicted to be in the inner leaflet region and to project toward functionally important residues in TM17 (Fig. 7) . Two of these residues, Trp 1246 and Tyr 1243 , together with Trp 553 and Phe 594 , have been postulated to form part of an aromatic basket at the cytoplasmic entrance to the translocation pathway (Ito et al., 2001; Koike et al., 2002; Zhang et al., 2002; Campbell et al., 2004) . Similar clusters of functionally important aromatic and polar amino acids are present in the inner leaflet regions of TM11 and TM16 (Fig. 7) . Although mutation of residues in these clusters has been shown to selectively affect the ability of MRP1 to confer resistance to various drugs and to transport E 2 17␤G, only mutations of and MSD2 of MRP1 has been described in detail by Campbell et al. (2004) . For clarity, other TMs in these two MSDs have been removed and the side chains of only selected residues have been shown using PyMol. Previously mutated residues in TMs 10, 16, and 17 that do or do not influence substrate specificity or overall activity are shown in red and blue, respectively. Residues in TM10 which, when mutated, alter substrate specificity or overall activity include: Thr 550 , Thr 556 , and Thr 564 (green), Trp 553 (yellow), Pro 557 (violet), and Tyr 568 (orange). The residue in TM17 indicated by the arrow is Arg 1249 , the side chain of which is approximately 7.5 Å from the side chain of Trp 553 . B, a schematic of TM10 and TM16 with mutated polar residues referred to in the text indicated by shaded circles.
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Phe 594 differentially affected transport of substrates including LTC 4 (Campbell et al., 2004) . Despite the cross-linking of LTC 4 to regions spanning these helices, amino acids important for specific interaction with this substrate seem to be located in other TM helices, including TMs 6, 9, and 15 .
The predicted location of Tyr 568 close to the extracellular/membrane interface distinguishes it from other polar residues in TM10 and the polar residues in TMs 11, 16, and 17 that influence substrate specificity. Many of the conjugated substrates of MRP1 are relatively hydrophilic, and it seems likely that they interact with the protein from the cytosol, rather than by diffusion through the membrane. Consequently, the predicted location of Tyr 568 at the distal end of the translocation pathway raised the possibility that it might be involved in a step in the transport of E 2 17␤G subsequent to initial binding, such as substrate translocation and release. However, kinetic analysis showed that the nonconservative mutation Y568A increased the apparent K m for E 2 17␤G approximately 5-fold, without altering V max . Thus, the mutation seems to affect a step that we are presently unable to distinguish kinetically from substrate binding. The side chain of Tyr 568 is predicted to be within 2 Å of Pro 343 in TM6, mutation of which results in a major decrease in transport of E 2 17␤G and, to a lesser extent, the transport of other substrates . Based on our current model of MRP1, the longest distance between side chains of residues in TM17 close to the cytosol/membrane interface that influence transport and those in the outer leaflet of TM6 and TM10 is approximately 22 Å. This is approximately equivalent to the longest dimension of E 2 17␤G. Thus, it is feasible that binding of at least some substrates may involve contacts that span both lipid bilayers. However, since binding of some substrates by MRP1 seems to cause conformational changes in the membrane-spanning domains (Manciu et al., 2003) , it is also possible that the interaction with residues such as Pro 343 and Tyr 568 may occur subsequent to a conformational change triggered by initial docking of E 2 17␤G with residues in the inner leaflet region of the protein.
